John Theurer Cancer Center at Hackensack University Medical Center Researchers Co-Author ZUMA-2 Three-Year Follow-Up on CAR T-Cell for Mantle Cell Lymphoma
Longest follow-up of CAR T-Cell in MCL to date showed long-term benefits for patients
CART cell brexu-cel is the first approved cell therapy in MCL after 1 line of therapy and a game changer based on ORR of 91% and 68% CR.
Researchers with John Theurer Cancer Center at Hackensack University Medical Center contributed to a 3-year follow-up ZUMA-2 study of brexucabtagene autoleucel (KTE-X19) autologous anti-CD19 chimeric antigen receptor (CAR) T-Cell therapy in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups in the ZUMA-2 Study. Here are a few key points of the research, which was published in the Journal of Clinical Oncology:
- This study is the longest follow-up of CAR T-Cell therapy in patients with MCL to date with at 3y 75% of the initial CR still durable, and very few late relapses (only 3 past 24 months) and overall close to 40% of the treated population likely cured.
- High-peak CAR T-Cell expansion in responders correlates with superior outcome and negative MRD at 3 and 6 months.
- Patients with high-risk features had similar response rates while patients with prior bendamustine (within 6 months) might have less CART expansion and worse outcome.
The study reviewed outcomes of a 3-year follow-up in the ZUMA-2 study of KTE-X19 in relapsed/refractory MCL, including for subgroups by prior therapy (bendamustine and type of Bruton tyrosine kinase inhibitor [BTKi]) or high-risk characteristics, after a single infusion of KTE-X19. The objective response rate among the 68 treated patients was 91%, with 68% complete responses.
Learn more about innovative cancer treatments at John Theurer Cancer Center at Hackensack University Medical Center.